|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 11/07/14 Cipher Pharmaceuticals Inc 40FR12B 84:13M Merrill Corp-MD/FA |
Document/Exhibit Description Pages Size
1: 40FR12B Registration of Securities of a Canadian Issuer -- HTML 97K
SEA'34 §12(b)
2: EX-99.01 Miscellaneous Exhibit HTML 31K
3: EX-99.02 Miscellaneous Exhibit HTML 376K
4: EX-99.03 Miscellaneous Exhibit HTML 154K
5: EX-99.04 Miscellaneous Exhibit HTML 44K
6: EX-99.05 Miscellaneous Exhibit HTML 61K
7: EX-99.06 Miscellaneous Exhibit HTML 317K
8: EX-99.07 Miscellaneous Exhibit HTML 32K
9: EX-99.08 Miscellaneous Exhibit HTML 32K
10: EX-99.09 Miscellaneous Exhibit HTML 23K
11: EX-99.10 Miscellaneous Exhibit HTML 557K
12: EX-99.11 Miscellaneous Exhibit HTML 28K
13: EX-99.12 Miscellaneous Exhibit HTML 444K
14: EX-99.13 Miscellaneous Exhibit HTML 27K
15: EX-99.14 Miscellaneous Exhibit HTML 29K
16: EX-99.15 Miscellaneous Exhibit HTML 45K
17: EX-99.16 Miscellaneous Exhibit HTML 27K
18: EX-99.17 Miscellaneous Exhibit HTML 264K
19: EX-99.18 Miscellaneous Exhibit HTML 131K
20: EX-99.19 Miscellaneous Exhibit HTML 28K
21: EX-99.20 Miscellaneous Exhibit HTML 28K
22: EX-99.21 Miscellaneous Exhibit HTML 44K
23: EX-99.22 Miscellaneous Exhibit HTML 41K
24: EX-99.23 Miscellaneous Exhibit HTML 25K
25: EX-99.24 Miscellaneous Exhibit HTML 344K
26: EX-99.25 Miscellaneous Exhibit HTML 169K
27: EX-99.26 Miscellaneous Exhibit HTML 29K
28: EX-99.27 Miscellaneous Exhibit HTML 29K
29: EX-99.28 Miscellaneous Exhibit HTML 40K
30: EX-99.29 Miscellaneous Exhibit HTML 27K
31: EX-99.30 Miscellaneous Exhibit HTML 35K
32: EX-99.31 Miscellaneous Exhibit HTML 351K
33: EX-99.32 Miscellaneous Exhibit HTML 174K
34: EX-99.33 Miscellaneous Exhibit HTML 28K
35: EX-99.34 Miscellaneous Exhibit HTML 28K
36: EX-99.35 Miscellaneous Exhibit HTML 41K
37: EX-99.36 Miscellaneous Exhibit HTML 23K
38: EX-99.37 Miscellaneous Exhibit HTML 23K
39: EX-99.38 Miscellaneous Exhibit HTML 24K
40: EX-99.39 Miscellaneous Exhibit HTML 28K
41: EX-99.40 Miscellaneous Exhibit HTML 406K
42: EX-99.41 Miscellaneous Exhibit HTML 173K
43: EX-99.42 Miscellaneous Exhibit HTML 45K
44: EX-99.43 Miscellaneous Exhibit HTML 40K
45: EX-99.44 Miscellaneous Exhibit HTML 42K
46: EX-99.45 Miscellaneous Exhibit HTML 29K
47: EX-99.46 Miscellaneous Exhibit HTML 28K
48: EX-99.47 Miscellaneous Exhibit HTML 310K
49: EX-99.48 Miscellaneous Exhibit HTML 32K
50: EX-99.49 Miscellaneous Exhibit HTML 32K
51: EX-99.50 Miscellaneous Exhibit HTML 559K
52: EX-99.51 Miscellaneous Exhibit HTML 27K
53: EX-99.52 Miscellaneous Exhibit HTML 424K
54: EX-99.53 Miscellaneous Exhibit HTML 26K
55: EX-99.54 Miscellaneous Exhibit HTML 264K
56: EX-99.55 Miscellaneous Exhibit HTML 156K
57: EX-99.56 Miscellaneous Exhibit HTML 29K
58: EX-99.57 Miscellaneous Exhibit HTML 29K
59: EX-99.58 Miscellaneous Exhibit HTML 44K
60: EX-99.59 Miscellaneous Exhibit HTML 28K
61: EX-99.60 Miscellaneous Exhibit HTML 35K
62: EX-99.61 Miscellaneous Exhibit HTML 32K
63: EX-99.62 Miscellaneous Exhibit HTML 33K
64: EX-99.63 Miscellaneous Exhibit HTML 29K
65: EX-99.64 Miscellaneous Exhibit HTML 33K
66: EX-99.65 Miscellaneous Exhibit HTML 340K
67: EX-99.66 Miscellaneous Exhibit HTML 195K
68: EX-99.67 Miscellaneous Exhibit HTML 29K
69: EX-99.68 Miscellaneous Exhibit HTML 29K
70: EX-99.69 Miscellaneous Exhibit HTML 46K
71: EX-99.70 Miscellaneous Exhibit HTML 354K
72: EX-99.71 Miscellaneous Exhibit HTML 202K
73: EX-99.72 Miscellaneous Exhibit HTML 29K
74: EX-99.73 Miscellaneous Exhibit HTML 29K
75: EX-99.74 Miscellaneous Exhibit HTML 44K
76: EX-99.75 Miscellaneous Exhibit HTML 23K
77: EX-99.76 Miscellaneous Exhibit HTML 369K
78: EX-99.77 Miscellaneous Exhibit HTML 32K
79: EX-99.78 Miscellaneous Exhibit HTML 32K
80: EX-99.79 Miscellaneous Exhibit HTML 23K
81: EX-99.80 Miscellaneous Exhibit HTML 425K
82: EX-99.81 Miscellaneous Exhibit HTML 32K
83: EX-99.82 Miscellaneous Exhibit HTML 32K
84: EX-99.83 Miscellaneous Exhibit HTML 22K
Exhibit 99.56
99.56 Canadian Form 52-109F2 — Certification of Interim Filings - CEO
Form 52-109F2 - Certification of Interim Filings
I, Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following:
1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim period ended March 31, 2014.
2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, for the period covered by the interim filings.
3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial statements together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
4. Responsibility: The issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.
5. Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer and I have, as at the end of the period covered by the interim filings
(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
5.1 Control framework: The control framework the issuer’s other certifying officer and I used to design the issuer’s ICFR is based on criteria established in the Internal Control — Integrated Framework (1992) issued by the Committee of Sponsoring Organizations (COSO).
5.2 ICFR - material weakness relating to design: N/A
5.3 Limitation on scope of design: N/A
6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on January 1, 2014 and ended on March 31, 2014 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.
|
Date: May 2, 2014 |
|
|
|
|
|
|
|
|
(signed) Larry Andrews |
|
|
|
|
|
|
|
|
| |
|
President and Chief Executive Officer |
|
| This ‘40FR12B’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/7/14 | F-X | ||
| 5/2/14 | ||||
| 3/31/14 | ||||
| 1/1/14 | ||||
| List all Filings | ||||